Hikma Pharmaceuticals Share News (HIK)

London midday: Resource stocks drag FTSE 100 into the red

UK stocks were trading firmly in the red by Monday lunchtime despite a positive start, with shares in the oil and mining sectors providing a drag. London's FTSE 100 was down 0.9% at 6,489 by midday, dropping sharply after reaching a high of 6,576.74 early on. This week will be the first full tradin

Hikma soars after bullish recommendation from brokers

Hikma Pharmaceuticals shares edged closer to an all-time high on Monday, in the wake of bullish recommendation from two brokers. The stock, which rose 66.8% in 2014, was among Europe's best performing small-cap after JP Morgan lifted its price target on Hikma shares by 18.4% and maintained an 'overw

BUZZ-Hikma: back near record highs, top-ranked brokers come out in favour

** Hikma Pharmaceuticals, up 3.7 pct and close to testing all-time high again after two 5-star rated brokers issue bullish recommendations on stock. ** Stock is Europe's best performing small-cap, extends 2014's stellar run that saw stock up 66.8 pct. ** JPMorgan lifts its PT on stock

Sector movers: Defensive pharma stocks fall as Santa Rally continues

Pharmaceutical and healthcare stocks were leading the fallers on Tuesday as investors dumped defensive assets amid a continued pre-Christmas rally. UK stocks have risen for six straight days as markets rebounded strongly following a recent sell-off. While more cyclical sectors such as construction

Thursday broker round-up

Aberdeen: Charles Stanley downgrades to 'hold'. Afren: Canaccord reduces target price from 115p to 65p, while staying with its 'speculative buy' recommendation. Amino Technologies: Northland moves target price from 120p to 130p and retains a 'buy' recommendation. Belgravium Technologies: WH Irelan

UK BROKER RATINGS: Citigroup Says Buy Boohoo, Cuts ASOS To Neutral

UK BROKER RATINGS: Goldman Sachs Says Buy Royal Mail And Intertek

UK MORNING BRIEFING: Goldman Sachs Ratings Lift Early FTSE Winners

FTSE 250 movers: Supergroup rises as Numis reaffirms rating

Supergroup rose after Numis Securities reaffirmed its 'hold' rating on the stock, with a target price of 1,100p which would suggest a potential upside of 41.21% from the stock's previous close. Since 31 October, three other analysts firms, Berenberg, Investec and Cantor Fitzgerald Europe, reiterated

UK MIDDAY BRIEFING: Morrisons Statement Also Boosts Peers

UK WINNERS & LOSERS: Supermarkets Gain As Morrisons Reports Progress

TOP NEWS: UK Industrial Production Beats Expectations

Hikma Raises Revenue Guidance, Working To Resolve Portugal Issues

UPDATE 1-Hikma raises full-year revenue forecast

(Adds details, analyst comment, share movement) Nov 6 (Reuters) - Drugmaker Hikma Pharmaceuticals Plc raised its full-year revenue growth target to 7 percent, citing strong demand for its high-margin injectible drugs, particularly in the United States. The Jordanian company, which ma

Hikma raises full-year revenue forecast

Nov 6 (Reuters) - Drugmaker Hikma Pharmaceuticals Plc raised its full-year revenue growth target to 7 percent, helped by strong demand for its high-margin injectible drugs, particularly in the United States. The company, which makes and markets branded and non-branded generics and injectib